Error message

Please note: Our system will be undergoing maintenance on Thursday, May 25th , 8:30 AM ET, through Monday, June 5th , 12:30 PM ET, During this time, SFB login and transaction-related services will be down. Should you have any urgent issues, please reach out directly to info@biomaterials.org. Thank you!

Biomaterials & Medical Products Commercialization

BMPC SIG members exchange ideas and experiences about the commercialization of medical products dependent upon biomaterials for utility, efficacy, safety, and reimbursement capability.  Society for Biomaterials members, ranging from students to veterans in the field, will find an open forum to explore issues facing commercial biomaterials, such as regulations, patents, litigation, reimbursement for the resultant medical device, manufacturing, and distribution with reference to hospital value analysis committees, purchasing & supply chain management system.  Translation from the development to marketing of safe and innovative medical products can be improved by the proper commercial valuation of Biomaterials through current scientific inputs to assist in a better Medical Billing System.  Accordingly, our mission through this SIG would be to take part in the efforts to explain the scientific, biological, and biochemical features of biomaterials to the clinical community.  This process would assist any clinical value analysis team to recommend the government payers (CMS & Private Insurance) to adopt an appropriate commercial valuation for each biomaterial-based medical device in the market.  Join the Biomaterials and Medical Products Commercialization SIG to enhance your knowledge and decision-making skills in the dynamic healthcare community.

Officers

Chair: Stephanie Steichen, Ph.D.
Senior Technical Service & Development Specialist
Dow
2200 W Salzburg Rd
Auburn, MI 48611
t: (203) 830-9803
e: stephanie.steichen@dupont.com 

Vice Chair: Eric Sussman, PhD
U.S. Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993
t: (301) 796-7008
e: eric.sussman@fda.hhs.gov

Secretary/Treasurer: Robert Hastings, MS, PE
Research Director
Depuy Synthes Joint Reconstruction
Department of Research
700 Orthopaedic Dr
PO Box 988
Warsaw, IN 46581-0988
T: (574) 372-7438
e: bhastin2@its.jnj.com

Program Chair: Subramanian Gunasekaran, PhD
President/CEO
Encoll Corporation
Dept of Research & Development
4576 Enterprise St
Fremont, CA 94538
t: (510) 795-8581
e: guna@encoll.com

Web Contact: TBD

Student Contact: Travis Prest
PhD Candidate
University of Pittsburgh
450 Technology drive
Pittsburgh
Pittsburgh, PA 15219
t: (724) 322-8501
e: travisprest@gmail.com

Biomaterials Forum Reporter: Subramanian Gunasekaran, PhD
President/CEO
Encoll Corporation
Dept of Research & Development
4576 Enterprise St
Fremont, CA 94538
t: (510) 795-8581
e: guna@encoll.com

Industry Representative: Elaine Duncan, MSME, RAC
President
Paladin Medical, Inc.
PO Box 560
Stillwater, MN 55082
t: (715) 549-6035
e: duncan@paladinmedical.com

Past Chair: Chair: Eric Sussman, PhD
U.S. Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993
t: (301) 796-7008

 

Click here for membership list  (member log-in required - only available to members of this committee)

 

Back to SIGs overview

SFB News

The Call for Abstracts deadline has been extended - Now Due MAY 8, 2023!